Cryosite Limited (ASX:CTE – Get Free Report) insider Mark Kerr sold 154,494 shares of the business’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of A$1.05 ($0.70), for a total value of A$162,218.70 ($108,145.80).
Mark Kerr also recently made the following trade(s):
- On Tuesday, April 23rd, Mark Kerr acquired 1,000,000 shares of Cryosite stock. The stock was purchased at an average price of A$0.83 ($0.55) per share, for a total transaction of A$830,000.00 ($553,333.33).
Cryosite Price Performance
The company has a current ratio of 2.32, a quick ratio of 1.76 and a debt-to-equity ratio of 87.26.
About Cryosite
Cryosite Limited offers outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns and biological, as well as logistics services to the clinical trials, research, and pharmaceutical industries.
See Also
- Five stocks we like better than Cryosite
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Albemarle Stock: Strong Fundamentals vs. Lithium Volatility
- Consumer Staples Stocks, Explained
- MongoDB Stock: Analysts Recommend Buying the Dip
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- UniFirst Stock: Value-Building Sends a Signal to the Market
Receive News & Ratings for Cryosite Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryosite and related companies with MarketBeat.com's FREE daily email newsletter.
